Therefore, glutamine metabolism-related specific pathways have been ideal targets for developing anti-cancer drugs, with glutamine uptake inhibitors, glutamine antimetabolites, and glutaminase inhibitors being potential approaches (9, 10). This evidence concerns the gene GLS and cancer.